Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body

Pfizer

Status and phase: Terminated; Phase 1

Conditions: Generalized Anxiety Disorder

Treatments: Drug: PD 0332334; Drug: cimetidine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00800280

A5361030

Details and patient eligibility

About

The purpose of this study is to estimate the effects of multiple doses of cimetidine on the pharmacokinetics of a single dose of PD 0332334 and to evaluate the safety and tolerability of PD 0332334 when co-administered with cimetidine.

Full description

Detailed Description:

Additional Study Purpose Details: Evaluate the effects of multiple doses of cimetidine on the pharmacokinetics (e.g., elimination from the body) of a single dose of PD 0332334.

On February 18th 2009, a decision to terminate further development for PD 0332334 was communicated to investigators in this study. The decision to terminate this study was not based on any safety concerns.

Enrollment: 12 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy
• male or female adults

Exclusion criteria

• Current or history of clinically significant medical illness
• Smokers
• Illicit drug use

Trial design

12 participants in 2 patient groups

Single dose PD 0332334

Experimental group

Treatment:

Drug: PD 0332334

Drug: PD 0332334

Single dose PD 0332334 with steady-state cimetidine

Experimental group

Treatment:

Drug: cimetidine

Drug: PD 0332334

Drug: PD 0332334